![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Once-Daily Dolutegravir (DTG; GSK1349572) Has a Renal Safety Profile Comparable to Raltegravir (RAL) and Efavirenz in Antiretroviral (ART)-Naive Adults: 48 Week Results From SPRING-2 (ING113086) and SINGLE (ING114467)
|
|
|
Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
LD Curtis,1 S Min,2 G Nichols,2 B Wynne,3 C Stainsby,1 A Aylott,1 S Piscitelli,2 J Goodrich,4 SPRING-2 and SINGLE teams
1-3GlaxoSmithKline, Research & Development, 1Uxbridge, UK; 2Research Triangle Park, NC, USA; 3Upper Merion, PA, USA; 4ViiV Healthcare, Research Triangle Park, NC, USA
![IAS1.gif](../images/070313/070313-6/IAS1.gif)
![IAS2.gif](../images/070313/070313-6/IAS2.gif)
![IAS3.gif](../images/070313/070313-6/IAS3.gif)
![IAS4.gif](../images/070313/070313-6/IAS4.gif)
![IAS5.gif](../images/070313/070313-6/IAS5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|